and 5-10% , respectively. The marrow ablative potential of 
cyclophosphamide/TBI leaves the patient susceptible to a 
wide variety of infectious and bleeding complications until 
the marrow recovery ensues. Aggressive supportive care will 
be used to prevent or treat these complications. Morbidity 
associated with the transplant process may be substantial. 
Mucositis, fevers, rigors, pain, diarrhea, nausea, vomiting 
are symptoms most patients experience at one time or another 
during the first six weeks post-transplant. These 
discomforts are fully explained in the consent forms. We 
expect no toxicity unique to this particular protocol since 
all components of the treatment plan have been used 
previously in other studies, but synergistic interactions 
that are unexpected could occur, and will be closely watched 
for. 
13 . 0 Response Criteria 
General : 
13.1 Criteria for Clinical Disease Response 
1. Complete Remission: WBC declines to < 9 x 10 J /ul 
with normal differential. No splenomegaly by 
physical exam. Normalization of bone marrow for at 
least 4 weeks. 
2. Partial Response: < 20 x 103 /ul and/or persistent 
splenomegaly. 
3. Treatment failure: failure of treatment to reduce 
the WBC to less than 20,000/mm3 after transplant 
or after three months of interferon; progressive 
rise in WBC or increasing splenic enlargement; 
13.2 Criteria for Cytogenetic Response 
1. Complete cytogenetic response: 0%-5% Ph- cells 
2. Major Response: < 35%, > 5% Ph+ cells 
3. Minor Response: 35-95% Ph+ cells 
4. Complete genetic remission: failure to detect bcr- 
abl RNA via reverse RNA polymerase chain reaction 
Interferon: 
13.3 Criteria for Point of Maximum Response (PMR) to 
Interferon 
Since this point cannot be precisely determined in 
Recombinant DNA Research, Volume 16 
[ 171 ] 
